



TROPHÉE DES FUTURES LICORNES

CorWave is pegged as a potential billion-euro company as part of “Future Unicorn” competition

Clichy, 15 March 2018 – CorWave has just been named among the 50 French companies (all sectors combined)¹ with the potential to reach a market valuation of over a billion euros as part of the “Future Unicorn Prize” challenge (Trophée des Futures Licornes), conducted in partnership with Entrepreneur Venture, Reputation Age, Euronext, Lyon Business School, Roland Berger and CB News.

The Future Unicorn Prize rewards early-stage French companies with a strong potential for growth and internationalisation. Several criteria for eligibility were taken into account: candidates needed to have been founded after 2003, with a head office in France, at least €5 million in capital raised, and a current market valuation of under €1 billion. Out of more than 60,000 companies studied, 1,400 were selected for an in-depth study. The jury was made up of figures from the world of finance and new technology. Based on a scoring system developed by the firm Roland Berger, 50 companies emerged as showing strong potential to become unicorns. Quality of management, access to capital and the disruptive nature of the technology were key criteria in selecting the future unicorns.

“Introducing our breakthrough technology into a highly concentrated market with close to a billion in annual sales would allow CorWave to become a corporation with critical mass in just a few years. It is extremely gratifying to be recognised as one of the French companies with the potential to be valued over a billion euros, all the more so since it's based on a method developed by a firm as serious as Roland Berger,” said Louis de Lillers, CEO of CorWave.

Created by MD Start, and backed by over twenty years of research initiated by an Arts et Métiers graduate at the CNRS laboratories, CorWave develops groundbreaking heart-pump technology in order to address a public health problem: chronic heart failure.

¹ Medtech/biotech – e-health, e-commerce and services, greentech, artificial intelligence and big data, Internet of things and SaaS.



CorWave's **wave membrane heart pump** technology differs from other LVADs on the market today because of its physiological design. CorWave pumps are able to mimic a pulse and produce blood flow velocity similar to that of a healthy heart. Closer to the natural functioning of the heart, CorWave pumps should drastically reduce the risk of complications and the costs associated with them.

To learn more about CorWave, please refer to the corporate profile attached.

Florence Portejoie

FP2COM

Relations presse CorWave

+ 33 (0) 6 07 76 82 83

fportejoie@fp2com.fr